Skip to main content
IMS Events Main banner
    22nd International Myeloma Society Annual Meeting
    Plenary

    Core Session 2: Risk Adaptation Management

    Wednesday, September 17, 2025
    14:30 - 15:50 East Coast USA Time
    Location: Hall FG

      Chair(s)

    • Thierry Facon, MD

      Pr
      University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
      Lille, France

      • Co-Chair(s)

    • Francesca Gay, MD (she/her/hers)

      Professor / Hematologist
      Division of Hematology 1, Clinical trial unit AOU città della salute e della scienza, University of Torino
      Torino, Piemonte, Italy

    Presentations:

    • 14:30 - 14:40 East Coast USA Time
      Risk assessment of newly diagnosed MM: genetic and biological risk factors

      Speaker: Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA

    • 14:40 - 14:50 East Coast USA Time
      Age or fitness - who should get a transplant?

      Speaker: Aurore Perrot, MD, PhD – University of Toulouse, University Hospital Department of Hematology, IUCT Oncopole, CRCT, Toulouse, France

    • 14:50 - 15:00 East Coast USA Time
      Optimal treatment for high risk mm

      Speaker: Martin F. Kaiser, MD, FRCP, FRCPath (he/him/his) – The Institute of Cancer Research; Royal Marsden Hospital

    • 15:00 - 15:10 East Coast USA Time
      Frailty adapted therapy in NDMM

      Speaker: Ashley Rosko, MD (she/her/hers) – The Ohio State University

    • 15:10 - 15:25 East Coast USA Time
      Future Directions and Challenges

      Speaker: Sonja Zweegman, MD, PhD – Amsterdam UMC

    • 15:25 - 15:50 East Coast USA Time
      Round Table discussion

      Panelist: Hira Mian, MD (she/her/hers) – McMaster University, Hamilton, ON, Canada

      Panelist: Gordon Cook, PhD, DSc – Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK

      Panelist: Arleigh McCurdy, MD MHA FRCPC – The Ottawa Hospital, University of Ottawa, Canada